Bristol Myers details PhIII win in first-line test of Reblozyl for reducing transfusions in early blood cancer patients
Reblozyl, a drug that spurs bone marrow to make more blood cells, helped nearly twice as many anemic patients with an early form of blood cancer prolong the need for transfusions compared to those who got an older therapy.
The results, which Bristol Myers Squibb announced Thursday evening, had been previously teased from a Phase III study called COMMANDS, which tested Reblozyl as a first-line treatment in about 350 adults with very low to intermediate risk myelodysplastic syndrome, or MDS, a blood cancer that prevents red blood cells from maturing and can progress into leukemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
